» Articles » PMID: 37310446

The 5-HT Receptor Biased Agonists, NLX-204 and NLX-101, Display Ketamine-like RAAD and Anti-TRD Activities in Rat CMS Models

Overview
Specialty Pharmacology
Date 2023 Jun 13
PMID 37310446
Authors
Affiliations
Soon will be listed here.
Abstract

Objectives: NLX-101 and NLX-204 are highly selective serotonin 5-HT 'biased' agonists, displaying potent and efficacious antidepressant-like activity upon acute administration in models such as the forced swim test.

Methods: we compared the effects of repeated administration of NLX-101, NLX-204 and ketamine in the chronic mild stress (CMS) model of depression, considered to have high translational potential, on sucrose consumption (anhedonia measure), novel object recognition (NOR; working memory measure) and elevated plus maze (EPM; anxiety measure) in male Wistar and Wistar-Kyoto rats (the latter being resistant to classical antidepressants).

Results: in Wistar rats, NLX-204 and NLX-101 (0.08-0.16 mg/kg i.p.), like ketamine (10 mg/kg i.p.) dose-dependently reversed CMS-induced sucrose intake deficit from treatment Day 1, with nearly full reversal observed at the higher dose at Days 8 and 15. These effects persisted for 3 weeks following treatment cessation. In the NOR test, both doses of NLX-101/NLX-204, and ketamine, rescued the deficit in discrimination index caused by CMS on Days 3 and 17; all three compounds increased time spent in open arms (EPM) but only NLX-204 achieved statistical significance on Days 2 and 16. In Wistar-Kyoto rats, all 3 compounds were also active in the sucrose test and, to a lesser extent, in the NOR and EPM. In non-stressed rats (both strains), the three compounds produced no significant effects in all tests.

Conclusions: these observations further strengthen the hypothesis that biased agonism at 5-HT receptors constitutes a promising strategy to achieve rapid-acting/sustained antidepressant effects combined with activity against TRD, in addition to providing beneficial effects against memory deficit and anxiety in depressed patients.

Citing Articles

Trends in research on novel antidepressant treatments.

Zelek-Molik A, Litwa E Front Pharmacol. 2025; 16:1544795.

PMID: 39931695 PMC: 11807967. DOI: 10.3389/fphar.2025.1544795.


Validation of Wistar-Kyoto rats kept in solitary housing as an animal model for depression using voxel-based morphometry.

Yoshii T, Oishi N, Sotozono Y, Watanabe A, Sakai Y, Yamada S Sci Rep. 2024; 14(1):3601.

PMID: 38351316 PMC: 10864298. DOI: 10.1038/s41598-024-53103-2.


Preclinical models of treatment-resistant depression: challenges and perspectives.

Kolasa M, Faron-Gorecka A Pharmacol Rep. 2023; 75(6):1326-1340.

PMID: 37882914 PMC: 10661811. DOI: 10.1007/s43440-023-00542-9.

References
1.
Maeng S, Zarate Jr C, Du J, Schloesser R, McCammon J, Chen G . Cellular mechanisms underlying the antidepressant effects of ketamine: role of alpha-amino-3-hydroxy-5-methylisoxazole-4-propionic acid receptors. Biol Psychiatry. 2007; 63(4):349-52. DOI: 10.1016/j.biopsych.2007.05.028. View

2.
Witkin J, Knutson D, Rodriguez G, Shi S . Rapid-Acting Antidepressants. Curr Pharm Des. 2018; 24(22):2556-2563. DOI: 10.2174/1381612824666180730104707. View

3.
Papp M, Gruca P, Lason-Tyburkiewicz M, Litwa E, Niemczyk M, Tota-Glowczyk K . Dopaminergic mechanisms in memory consolidation and antidepressant reversal of a chronic mild stress-induced cognitive impairment`. Psychopharmacology (Berl). 2017; 234(17):2571-2585. PMC: 5548836. DOI: 10.1007/s00213-017-4651-4. View

4.
Reus G, Vieira F, Abelaira H, Michels M, Tomaz D, Dos Santos M . MAPK signaling correlates with the antidepressant effects of ketamine. J Psychiatr Res. 2014; 55:15-21. DOI: 10.1016/j.jpsychires.2014.04.010. View

5.
Becker G, Bolbos R, Costes N, Redoute J, Newman-Tancredi A, Zimmer L . Selective serotonin 5-HT1A receptor biased agonists elicitdistinct brain activation patterns: a pharmacoMRI study. Sci Rep. 2016; 6:26633. PMC: 4876409. DOI: 10.1038/srep26633. View